Patents by Inventor Friedhelm Bladt

Friedhelm Bladt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for detecting protein modifications using specific antibodies
    Patent number: 10996225
    Abstract: Method, kit and composition for analyzing analytes for modifications using modification site specific antibodies to bind an analyte with his specific modification sites of interest to different dyes simultaneously with an antibody which is specific to the non-modificated analyte binding to another dye to determine the concentration of the analyte for quantification of the modified analyte in the identical sample.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 4, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Frank Jeahrling, Friedhelm Bladt, Jessica Witzgall
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
    Patent number: 10532052
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: January 14, 2020
    Assignee: Merck Patent GmbH
    Inventors: Friedhelm Bladt, Manja Friese-Hamim
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
    Publication number: 20190388423
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
    Patent number: 10231972
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with 4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: March 19, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Friedhelm Bladt, Manja Friese-Hamim
  • COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH A QUINAZOLINE DERIVATIVE
    Publication number: 20170340635
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with 4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 30, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
    Publication number: 20170319581
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • METHOD FOR DETECTING PROTEIN MODIFICATIONS USING SPECIFIC ANTIBODIES
    Publication number: 20170023581
    Abstract: Method, kit and composition for analyzing analytes for modifications using modification site specific antibodies to bind an analyte with his specific modification sites of interest to different dyes simultaneously with an antibody which is specific to the non-modificated analyte binding to another dye to determine the concentration of the analyte for quantification of the modified analyte in the identical sample.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 26, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Frank JEAHRLING, Friedhelm BLADT, Jessica WITZGALL
  • A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (RCC)
    Publication number: 20160331748
    Abstract: 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of renal cell carcinoma (RCC).
    Type: Application
    Filed: December 16, 2014
    Publication date: November 17, 2016
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH GEFITINIB
    Publication number: 20160324855
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with Gefitinib.
    Type: Application
    Filed: December 16, 2014
    Publication date: November 10, 2016
    Applicant: Merck Patente GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
    Publication number: 20150297594
    Abstract: A pharmaceutical composition comprising 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof and N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide or a pharmaceutically acceptable salt and/or solvate thereof.
    Type: Application
    Filed: September 13, 2013
    Publication date: October 22, 2015
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC)
    Publication number: 20150283137
    Abstract: 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC).
    Type: Application
    Filed: October 4, 2013
    Publication date: October 8, 2015
    Applicant: Merck Patent GmbH
    Inventors: Manja Friese-Hamim, Friedhelm Bladt
  • COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS
    Publication number: 20150044211
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with a compound selected from the group erlotinib, cetuximab, aflibercept, bevacizumab.
    Type: Application
    Filed: February 21, 2013
    Publication date: February 12, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Friedhelm Bladt, Manja Friese-Hamim